Gyre Therapeutics, Inc.GYRE
What Gyre Therapeutics, Inc. does.
In this section, unless otherwise specified, references to “we,” “our,” “us” and “our company” refer to Gyre Therapeutics, Inc. and our majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd.) (“Gyre Pharmaceuticals”).
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S. operations headquartered in San Diego, California.
In the PRC, we have established a strong commercial and operational foundation in fibrotic diseases through the successful development and commercialization of ETUARY® (pirfenidone), which has generated consistent revenue and positioned us as a leading participant in the treatment of pulmonary fibrosis.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $20.9M | $7.3M | $102.3M | $113.5M | $105.8M | $116.6M |
| Net income | -$56.2M | -$87.9M | $4.3M | -$85.5M | $17.9M | $9.9M |
| Free cash flow | — | -$84.6M | $5.7M | $17.4M | -$6.0M | -$180,000 |
More on GYRE.
- Gyre Therapeutics, Inc. summary
- Gyre Therapeutics, Inc. financial statements
- Gyre Therapeutics, Inc. key metrics
- Gyre Therapeutics, Inc. health scores and style box
- Gyre Therapeutics, Inc. earnings
- Gyre Therapeutics, Inc. dividends
- Gyre Therapeutics, Inc. valuation
- Gyre Therapeutics, Inc. ownership and insiders
- Gyre Therapeutics, Inc. peers
Figures from Gyre Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.